Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus CORDRAN N.
ALA-SCALP vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Topical application of a 5% solution to the scalp twice daily.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic